INmune Bio, Inc.
NASDAQ:INMBBiotechnology
Healthcare
$1.89 +8.38%
+$0.15 today
- Market cap
- $50.25M
- Beta
- 0.98
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$1.56
52W Low $1.09High $3.24
Volume 0.09M
Average 0.68M
Income Statement
Follow revenue through to earnings.
Revenue
$50,000.00
FY 2025 · Annual
+257.1% YoYOperating Income
-$30.87M
FY 2025 · Annual
Net Income
-$45.93M
FY 2025 · Annual
Income Statement
USD
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 181K | 374K | 155K | 14K | 50K |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 181K | 374K | 155K | 14K | 50K |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 20.54M | 17.07M | 20.27M | 33.17M | 20.66M |
| Selling, General & Admin | 8.79M | 9.26M | 9.62M | 9.48M | 10.26M |
| Operating Expenses | 29.33M | 26.33M | 29.9M | 42.65M | 30.92M |
| Depreciation & Amortization | 29.15M | 25.95M | 29.74M | 553K | 84K |
| EBITDA | (1.19M) | (1.35M) | (267K) | (41.53M) | (45.85M) |
| EBITDA Margin | -655.8% | -360.4% | -172.3% | -296635.7% | -91698.0% |
| Operating Income | (29.15M) | (25.95M) | (29.74M) | (42.64M) | (30.87M) |
| Operating Margin | -16106.6% | -6938.8% | -19187.7% | -304535.7% | -61738.0% |
| Interest Income | 0 | 0 | 0 | 0 | 850K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (1.19M) | (1.35M) | (267K) | 553K | (15.06M) |
| Income Before Tax | (30.34M) | (27.3M) | (30.01M) | (42.08M) | (45.93M) |
| Pre-Tax Margin | -16762.4% | -7299.2% | -19360.0% | -300585.7% | -91866.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (30.34M) | (27.3M) | (30.01M) | (42.08M) | (45.93M) |
| Net Margin | -16762.4% | -7299.2% | -19360.0% | -300585.7% | -91866.0% |
| EPS (Basic) | (1.88) | (1.52) | (1.67) | (2.11) | (1.86) |
| EPS (Diluted) | (1.88) | (1.52) | (1.67) | (2.11) | (1.86) |
| 16.13M | 17.93M | 17.98M | 19.94M | 26.59M | |
| 16.13M | 17.93M | 17.98M | 19.94M | 26.59M |
INMB Earnings Waterfall · TTM
NASDAQ:INMB · Revenue to Net Income
Key Ratios
EPS$-1.69
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-1.5
P/S Ratio0.0
Analysis
$0 of revenue converted into -$41.6M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.69, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 3 | Initial statement of beneficial ownership | Sep 23, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 23, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 17, 2026 | |
| 3 | Initial statement of beneficial ownership | Sep 16, 2026 | |
| 8-K | Current report | Sep 14, 2026 |
How much revenue does INMB generate?
INmune Bio, Inc. (INMB) reported $50,000.00 of revenue in fiscal 2025.
Is INMB profitable?
INmune Bio, Inc. (INMB) reported -$45.93M of net income, with a net margin of -91866.0%.
Continue the stock analysis
Jump to another research area for this company.